184 related articles for article (PubMed ID: 2368239)
1. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.
Takashi M; Sakata T; Nagai T; Kato T; Sahashi M; Koshikawa T; Miyake K
Urology; 1990 Jul; 36(1):96-8. PubMed ID: 2368239
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.
Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF
Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
Scher HI; Yagoda A; Herr HW; Sternberg CN; Morse MJ; Sogani PC; Watson RC; Reuter V; Whitmore WF; Fair WR
J Urol; 1988 Mar; 139(3):475-7. PubMed ID: 3343729
[TBL] [Abstract][Full Text] [Related]
4. [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report].
Hatano K; Kawashima A; Arai Y; Inoue H; Miyagawa Y; Takaha N; Nishimura K; Miyake O; Okuyama A
Hinyokika Kiyo; 2006 Oct; 52(10):801-3. PubMed ID: 17131872
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
6. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
7. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
Koch MO; Coussens D
Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
[No Abstract] [Full Text] [Related]
8. [Primary transitional cell carcinoma of prostate: a case report].
Uemura M; Imamura R; Inoue H; Nishimura K; Mizutani S; Miyoshi S; Mise T
Hinyokika Kiyo; 2000 Jul; 46(7):495-8. PubMed ID: 10965459
[TBL] [Abstract][Full Text] [Related]
9. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
Bishop JR; Moul JW; Maldonado L; McLeod DG
Urology; 1990 Oct; 36(4):373-7. PubMed ID: 2219624
[TBL] [Abstract][Full Text] [Related]
10. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.
Connor JP; Olsson CA; Benson MC; Rapoport F; Sawczuk IS
Urology; 1989 Dec; 34(6):353-6. PubMed ID: 2595880
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
[TBL] [Abstract][Full Text] [Related]
14. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic changes of transitional cell carcinoma of bladder after M-VAC chemotherapy.
Javadpour N; Daloni P
Urology; 1989 Dec; 34(6):357-9. PubMed ID: 2595881
[TBL] [Abstract][Full Text] [Related]
16. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
17. [Primary carcinoma of the female urethra].
Takahashi H; Hirano A; Nakano M; Tanaka K; Shinagawa T
Hinyokika Kiyo; 1989 Nov; 35(11):1943-5. PubMed ID: 2618893
[TBL] [Abstract][Full Text] [Related]
18. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
[No Abstract] [Full Text] [Related]
19. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
